William M. Southerland to Drug Administration Schedule
This is a "connection" page, showing publications William M. Southerland has written about Drug Administration Schedule.
Connection Strength
0.068
-
Das JR, Fryar-Tita EB, Zhou Y, Green S, Southerland WM, Bowen D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res. 2007 Nov-Dec; 27(6B):3791-9.
Score: 0.019
-
Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer Res. 2007 Mar-Apr; 27(2):825-33.
Score: 0.018
-
Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Res. 2006 May-Jun; 26(3A):1861-7.
Score: 0.017
-
De Soto JA, Bowen D, Davis JH, Southerland WM, Hawkins M. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. Anticancer Res. 2002 Mar-Apr; 22(2A):1007-9.
Score: 0.013